Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.
Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.